20.02.2014 • NewsBayerBoehringer IngelheimDede Willams

Drug Maker Boehringer Facing U.S. Lawsuits

German pharmaceutical producer Boehringer Ingelheim is being confronted in the U.S. with more than 2,000 lawsuits related to its blood thinner Pradaxa (dabigatran). The plaintiffs charge that treatment with the drug led to severe bleeding and in some cases death.

On the U.S. market since 2008 - since 2010 in the U.S. - Pradaxa is one of a new class of blood thinners used in stroke prevention and is designed to replace the widely used generic drug warfarin, which requires extensive blood testing.

Newer products such as Pradaxa as well as Xarelto, launched by Bayer and Johnson & Johnson, and Eliquis developed by Pfizer and BMS, have been touted as requiring less monitoring while being at least as effective at preventing strokes and blood clots in patients with atrial fibrillation.

According to U.S. press reports, Pradaxa has been prescribed to 850,000 patients across the country and sales have totalled $2 billion since 2010. The drug has been unofficially linked to more than 1,000 deaths.

The U.S. Food and Drug Administration, FDA, recently agreed to conduct new studies on the risks of the new anti-coagulants.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.